These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
2. 99mTc-MIBI scintigraphy in musculoskeletal tumors. Pinkas L; Robinson D; Halperin N; Mindlin L; Cohenpour M; Baumer M; Home T J Nucl Med; 2001 Jan; 42(1):33-7. PubMed ID: 11197977 [TBL] [Abstract][Full Text] [Related]
3. Technetium-99m-MIBI uptake in benign and malignant bone lesions: a comparative study with technetium-99m-MDP. Caner B; Kitapçl M; Unlü M; Erbengi G; Calikoğlu T; Göğüş T; Bekdik C J Nucl Med; 1992 Mar; 33(3):319-24. PubMed ID: 1531501 [TBL] [Abstract][Full Text] [Related]
4. Evaluating benign and malignant musculoskeletal lesions with radionuclide angiography and SPECT using Tc-99m MIBI. Ishiyama K; Tomura N; Okada K; Nagasawa H; Sashi R; Sasaki K; Sato K; Watarai J Clin Nucl Med; 2005 Sep; 30(9):598-603. PubMed ID: 16100476 [TBL] [Abstract][Full Text] [Related]
5. [Preliminary application of 99Tc(m)-MIBI scintigraphy for judgment of bone malignant and benign lesions]. Jia ZY; Deng HF Sichuan Da Xue Xue Bao Yi Xue Ban; 2007 Jul; 38(4):689-92. PubMed ID: 17718443 [TBL] [Abstract][Full Text] [Related]
6. 99mTc-MIBI in the assessment of response to chemotherapy and detection of recurrences in bone and soft tissue tumours of the extremities. Moustafa H; Riad R; Omar W; Zaher A; Ebied E Q J Nucl Med; 2003 Mar; 47(1):51-7. PubMed ID: 12714955 [TBL] [Abstract][Full Text] [Related]
7. Tc-99m MIBI uptake in traumatic vertebral fractures and metastatic vertebral lesions: comparison with Tc-99m MDP. Buyukdereli G; Ermin T; Kara O; Kibar M Adv Ther; 2006; 23(1):33-8. PubMed ID: 16644620 [TBL] [Abstract][Full Text] [Related]
8. Comparison of Tc-99m MIBI and Tl-201 uptake in musculoskeletal lesions. Adalet I; Ozger H; Cantez S Clin Nucl Med; 1996 Feb; 21(2):118-21. PubMed ID: 8697680 [TBL] [Abstract][Full Text] [Related]
9. Value of Tc-99m sestamibi scintigraphy in the detection of bone lesions in multiple myeloma: comparison with Tc-99m methylene diphosphonate. Alexandrakis MG; Kyriakou DS; Passam F; Koukouraki S; Karkavitsas N Ann Hematol; 2001 Jun; 80(6):349-53. PubMed ID: 11475149 [TBL] [Abstract][Full Text] [Related]
10. Correlation of 99mTc-sestamibi uptake with blood-pool and osseous phase 99mTc-MDP uptake in malignant bone and soft-tissue tumours. Ozcan Z; Burak Z; Erinç R; Dirlik A; Başdemir G; Sabah D; Ozkiliç H Nucl Med Commun; 2001 Jun; 22(6):679-83. PubMed ID: 11403180 [TBL] [Abstract][Full Text] [Related]
11. Assessment of P-glycoprotein in patients with malignant bone and soft-tissue tumors using technetium-99m-MIBI scintigraphy. Taki J; Sumiya H; Asada N; Ueda Y; Tsuchiya H; Tonami N J Nucl Med; 1998 Jul; 39(7):1179-84. PubMed ID: 9669390 [TBL] [Abstract][Full Text] [Related]
12. Potential of (99m)Tc-MIBI for detecting bone marrow metastases. Wakasugi S; Noguti A; Katuda T; Hashizume T; Hasegawa Y J Nucl Med; 2002 May; 43(5):596-602. PubMed ID: 11994520 [TBL] [Abstract][Full Text] [Related]
13. Evaluating benign and malignant bone and soft-tissue lesions with technetium-99m-MIBI scintigraphy. Taki J; Sumiya H; Tsuchiya H; Tomita K; Nonomura A; Tonami N J Nucl Med; 1997 Apr; 38(4):501-6. PubMed ID: 9098190 [TBL] [Abstract][Full Text] [Related]
14. Prognostic value of Tc-99m-MIBI performed during middle course of preoperative chemotherapy in patients with malignant bone and soft-tissue tumors. Wakabayashi H; Taki J; Inaki A; Sumiya H; Zen Y; Tsuchiya H; Kinuya S Clin Nucl Med; 2012 Jan; 37(1):1-8. PubMed ID: 22157020 [TBL] [Abstract][Full Text] [Related]
15. Comparison of technetium-99m-MIBI and technetium-99m-tetrofosmin uptake by musculoskeletal sarcomas. Söderlund V; Jonsson C; Bauer HC; Brosjö O; Jacobsson H J Nucl Med; 1997 May; 38(5):682-6. PubMed ID: 9170427 [TBL] [Abstract][Full Text] [Related]
16. 99mTc-MIBI scintigraphy in untreated stage III multiple myeloma: comparison with X-ray skeletal survey and bone scintigraphy. Alper E; Gurel M; Evrensel T; Ozkocaman V; Akbunar T; Demiray M Nucl Med Commun; 2003 May; 24(5):537-42. PubMed ID: 12717071 [TBL] [Abstract][Full Text] [Related]
17. Technetium-99m-sestamibi scintigraphy in multiple myeloma and related gammopathies: a useful tool for the identification and follow-up of myeloma bone disease. Balleari E; Villa G; Garrè S; Ghirlanda P; Agnese G; Carletto M; Clavio M; Ferrando F; Gobbi M; Mariani G; Ghio R Haematologica; 2001 Jan; 86(1):78-84. PubMed ID: 11146575 [TBL] [Abstract][Full Text] [Related]
18. Differentiation of malignant and degenerative benign bone disease using Tc-99m MDP and Tc-99m citrate scintigraphy. Sharma R; Mondal A; Bhatnagar A; Chakravarty KL; Mishra P; Chopra MK; Rawat HS; Kashyap R Clin Nucl Med; 1998 Nov; 23(11):758-63. PubMed ID: 9814564 [TBL] [Abstract][Full Text] [Related]
19. Multiple brown tumors with Tc-99m MDP superscan appearance and negative Tc-99m MIBI uptake. Zanglis A; Andreopoulos D; Zissimopoulos A; Baziotis N Clin Nucl Med; 2006 Oct; 31(10):640-3. PubMed ID: 16985376 [No Abstract] [Full Text] [Related]
20. Myositis ossificans demonstrated by positive gallium-67 and technetium-99m-HMDP bone imaging but negative technetium-99m-MIBI imaging. Shih WJ; Hackett MT; Stipp V; Gross K; Pulmano C J Nucl Med Technol; 1999 Mar; 27(1):48-50. PubMed ID: 10322577 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]